Equity · Healthcare
KYMR
NASDAQKymera Therapeutics (KYMR)
The line runs 114.84 USD on 26 October through 131.70 USD on 6 November, on a scale from 110 to 140. Days the market did not trade hold the previous close, flat.
- Market cap
- 11.2B USD
- Revenue, year to Dec 2025
- 39.2M USD
- EPS, diluted, year to Dec 2025
- −3.69 USD
- 52-week range
- 59 USD – 136.26 USD
- Avg volume
- 290.3K
- Mentions, 30 days
- 1
as of Nov 6, 2026
Have Kymera Therapeutics (KYMR) insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Kymera Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 25 Jun 2026, show no open-market purchase.
Form 4, 90 days to 9 Nov 2026, newest reported trade 1 Oct 2026
Buys 0Sells 2Net sold $4.16MOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | Mainolfi NelloChief Executive Officer | Sell | 30,000 | 3.4M USD |
| 04 Sep 2026 | Adams BrianChief Legal Officer | Sell | 6,371 | 744K USD |
| Sold | 2 open-market sales | 36,371 | $4.16M |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 01 Oct 2026 | Mainolfi NelloChief Executive Officer | Option exercise | 30,000 | 62K USD |
Which funds hold Kymera Therapeutics (KYMR)?
1 of the 45 institutional funds we track reported a Kymera Therapeutics position for the quarter ended 30 Sep 2026 — a combined 36.1M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Added | 323,219 | 36.1M USD | +2,438.6% |
What has been filed or recorded for Kymera Therapeutics (KYMR)?
The filings we hold for Kymera Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 14 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 14 Oct 2026 | Fails to deliver | Shares failed to deliver | 1 shares | 107 USD notional · <0.001% of shares out |
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,615 shares | 405K USD notional · 0.004% of shares out |
| 02 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,833 shares | 202K USD notional · 0.002% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.32 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.8B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 1.6B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.62 USD | Revenue $65M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.71 USD | Revenue $34M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.69 USD | Revenue $39M |
| 31 Dec 2025 | Financials | Revenue | 39.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −311.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.69 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.94 USD | Revenue $3M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.95 USD | Revenue $11M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.82 USD | Revenue $22M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.98 USD | Revenue $47M |
What is Reddit saying about Kymera Therapeutics (KYMR)?
Reddit mentioned KYMR 1 times in the 30 days to 8 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 0% read bullish, 0% bearish and 100% neither. Reddit data updated 8 November 2026.
30-day window, Method
Mentions, 30 days 1Communities 1
How do Reddit mentions of Kymera Therapeutics (KYMR) compare with its price?
Share ↗
Before our first record — not zero
Where Kymera Therapeutics (KYMR) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 1 | +0.00 |
Kymera Therapeutics (KYMR): frequently asked questions
What did Kymera Therapeutics shares close at?
Kymera Therapeutics closed at 131.70 USD on 6 Nov 2026, up 2.78% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Kymera Therapeutics’ market cap?
Kymera Therapeutics is worth 11.2B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Kymera Therapeutics’ revenue?
Kymera Therapeutics reported revenue of 39.2M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Kymera Therapeutics insiders bought or sold shares recently?
In the 90 days to 9 Nov 2026, Kymera Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 25 Jun 2026, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Kymera Therapeutics?
1 of the 45 funds we track reported a Kymera Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Kymera Therapeutics last report earnings?
Kymera Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.32 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Kymera Therapeutics?
Kymera Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 0% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings